Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

Alkermes (ALKS) Alkermes (NASDAQ:ALKS) is making strides in the biotech space. The company is active in areas of critical and chronic conditions like schizophrenia, bipolar disorder and opioid ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...

Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.

2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024. "The first quarter of 2024 marks our first full quarter as a profitable ...

DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk.

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...